Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
NKTR

NKTR - Nektar Therapeutics Stock Price, Fair Value and News

1.17USD-0.08 (-6.40%)Market Closed

Market Summary

NKTR
USD1.17-0.08
Market Closed
-6.40%

NKTR Stock Price

View Fullscreen

NKTR RSI Chart

NKTR Valuation

Market Cap

214.8M

Price/Earnings (Trailing)

-1.22

Price/Sales (Trailing)

2.38

EV/EBITDA

-0.98

Price/Free Cashflow

-1.14

NKTR Price/Sales (Trailing)

NKTR Profitability

EBT Margin

-195.21%

Return on Equity

-139.08%

Return on Assets

-44.5%

Free Cashflow Yield

-88.05%

NKTR Fundamentals

NKTR Revenue

Revenue (TTM)

90.2M

Rev. Growth (Yr)

0.21%

Rev. Growth (Qtr)

-9.4%

NKTR Earnings

Earnings (TTM)

-176.2M

Earnings Growth (Yr)

73.14%

Earnings Growth (Qtr)

11.73%

Breaking Down NKTR Revenue

Last 7 days

-7.1%

Last 30 days

-36.1%

Last 90 days

36.1%

Trailing 12 Months

107.3%

How does NKTR drawdown profile look like?

NKTR Financial Health

Current Ratio

6.1

NKTR Investor Care

Buy Backs (1Y)

2.96%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202490.2M000
202388.8M87.7M88.3M90.1M
2022103.1M96.3M95.0M92.1M
2021126.0M105.5M100.4M101.9M
2020137.0M162.5M163.3M152.9M
20191.2B119.1M120.6M114.6M
2018529.1M750.5M971.9M1.2B
2017131.3M133.1M249.7M307.7M
2016180.9M191.0M167.4M165.4M
2015289.7M283.9M211.0M230.8M
2014145.7M140.3M212.3M200.7M
201386.2M96.4M138.9M148.9M
201278.1M84.5M75.8M81.2M
2011137.1M111.9M101.0M71.5M
201093.7M115.5M137.3M159.0M
200900071.9M

Tracking the Latest Insider Buys and Sells of Nektar Therapeutics

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
chess robert
sold
-23,400
1.2
-19,500
-
May 17, 2024
zalevsky jonathan
sold
-12,871
1.75
-7,355
chief r&d officer
May 17, 2024
robin howard w
sold
-29,137
1.75
-16,650
president & ceo
May 17, 2024
wilson mark andrew
sold
-10,955
1.75
-6,260
chief legal officer
May 10, 2024
deep track capital, lp
sold
-99,629
1.7791
-56,000
-
Feb 20, 2024
robin howard w
sold
-13,622
0.68
-20,033
president & ceo

1–10 of 50

Which funds bought or sold NKTR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
new
-
23,157
23,157
-%
May 20, 2024
Virtu Financial LLC
new
-
16,000
16,000
-%
May 16, 2024
Tidal Investments LLC
new
-
21,515
21,515
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-71.3
-41,012
37,045
-%
May 15, 2024
HSBC HOLDINGS PLC
unchanged
-
28,761
70,857
-%
May 15, 2024
Royal Bank of Canada
reduced
-54.12
-
-
-%
May 15, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-38.26
3,248
158,580
-%
May 15, 2024
Cetera Advisor Networks LLC
new
-
11,330
11,330
-%
May 15, 2024
Shay Capital LLC
new
-
1,942,830
1,942,830
0.30%
May 15, 2024
AMERIPRISE FINANCIAL INC
reduced
-51.2
-49,346
206,080
-%

1–10 of 48

Are Funds Buying or Selling NKTR?

Are funds buying NKTR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NKTR
No. of Funds

Unveiling Nektar Therapeutics's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 15, 2024
tcg crossover gp ii, llc
9.9%
20,046,350
SC 13G
Feb 14, 2024
deep track capital, lp
9.65%
18,400,000
SC 13G/A
Feb 14, 2024
citadel advisors llc
3.0%
6
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
6.31%
12,042,873
SC 13G/A
Aug 17, 2023
ra capital management, l.p.
9.8%
18,700,000
SC 13G
Jul 10, 2023
invesco ltd.
2.9%
5,535,430
SC 13G/A
Jul 10, 2023
vanguard group inc
6.37%
12,056,187
SC 13G/A
Jul 07, 2023
blackrock inc.
4.5%
8,604,322
SC 13G/A
Jul 07, 2023
primecap management co/ca/
4.31%
8,149,876
SC 13G/A

Recent SEC filings of Nektar Therapeutics

View All Filings
Date Filed Form Type Document
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
Jun 05, 2024
EFFECT
EFFECT
Jun 05, 2024
424B3
Prospectus Filed
May 28, 2024
S-3
S-3
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 17, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Nektar Therapeutics)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Nektar Therapeutics News

Latest updates
Defense World21 hours ago
Yahoo Singapore News12 Jun 202412:16 pm
Investing.com14 May 202403:25 am

Nektar Therapeutics Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-9.4%21,639,00023,885,00024,144,00020,499,00021,594,00022,023,00023,625,00021,585,00024,822,00025,009,00024,921,00028,330,00023,647,00023,462,00030,033,00048,847,00050,573,00033,862,00029,218,00023,315,00028,222,000
Costs and Expenses-0.6%57,066,00057,396,00069,008,00071,098,000156,304,00074,492,00077,926,000174,421,000141,382,000137,919,000138,517,000138,535,000133,039,000134,183,000133,083,000126,556,000184,204,000143,500,000127,958,000134,285,000148,909,000
  S&GA Expenses16.3%20,149,00017,320,00021,147,00017,869,00021,081,00021,939,00022,534,00020,521,00027,339,00032,142,00029,468,00029,555,00031,679,00027,136,00026,982,00024,347,00026,217,00027,142,00023,983,00022,581,00025,006,000
  R&D Expenses-8.5%27,408,00029,942,00024,070,00029,681,00030,469,00034,740,00033,590,00042,740,000107,253,00099,614,000103,738,000101,313,00095,604,000102,724,000100,531,00096,436,000108,987,000110,369,00099,048,000106,686,000118,463,000
EBITDA Margin37.1%-1.87-2.98-3.19-3.35-4.51-3.82-4.64-5.30-4.62-5.00-4.79-4.36---------
Interest Expenses----------------647,0006,204,0005,428,0005,425,0005,231,0005,226,000
Income Taxes-20.7%-35,000-29,000-61,000-47,000-63,0003,144,000-155,000100,000126,000-4,000112,000357,00092,000128,00021,000144,000200,000278,00099,00099,000137,000
Earnings Before Taxes12.5%-36,837,000-42,108,000-45,898,000-51,169,000-137,081,000-56,544,000-59,204,000-158,968,000-90,267,000-145,649,000-129,594,000-125,162,000-122,875,000-117,075,000-108,565,000-79,856,000-138,451,000-111,886,000-98,486,000-110,187,000-119,495,000
EBT Margin36.3%-1.95-3.07-3.29-3.46-4.64-3.96-4.78-5.44-4.76-5.13-4.93-4.49---------
Net Income11.7%-36,802,000-41,694,500-45,837,000-51,891,000-137,018,000-57,671,000-59,049,000-160,727,000-92,768,000-145,645,000-129,706,000-125,798,000-123,793,000-117,203,000-108,586,000-80,000,000-138,651,000-112,164,000-98,585,000-110,286,000-119,632,000
Net Income Margin36.3%-1.95-3.07-3.30-3.47-4.65-4.02-4.82-5.49-4.79-5.15-4.95-4.51---------
Free Cashflow-1.6%-48,045,000-47,284,000-42,154,000-51,685,000-52,348,000-58,215,000-83,068,000-75,773,000-92,627,000-157,434,000-104,072,000-86,182,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.5%3963984424945627117818621,0241,1171,2771,3711,4571,5391,5091,5951,8881,9772,0882,1002,166
  Current Assets-3.3%3203313994414915465996667337969861,0561,0991,1381,0441,1521,4291,4221,5791,5971,490
    Cash Equivalents37.9%49.0035.0065.0051.0077.0088.0010678.0068.0025.0054.0015215019956.0058.0022796.0081.0085.00107
  Inventory0.9%16.0016.0015.0021.0020.0019.0019.0017.0015.0016.0015.0015.0017.0015.0013.0013.0014.0013.0014.0013.0012.00
  Net PPE-7.3%17.0019.0020.0023.0027.0032.0037.0040.0061.0061.0059.0059.0059.0060.0060.0061.0062.0066.0065.0065.0058.00
  Goodwill------77.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.0077.00
Liabilities0.8%269267283297321344369403416438476466462461338339592572600542533
  Current Liabilities2.2%52.0051.0052.0051.0060.0068.0084.0010510585.00140131124116127124377354125113100
Shareholder's Equity-3.3%1271311591972413674124596086808029059951,0771,1711,2561,2961,4051,4891,5571,634
  Retained Earnings-1.1%-3,514-3,477-3,435-3,389-3,338-3,201-3,141-3,082-2,923-2,832-2,687-2,557-2,432-2,309-2,191-2,083-2,003-1,864-1,751-1,652-1,542
  Additional Paid-In Capital1.0%3,6443,6083,6013,5933,5853,5753,5623,5493,5383,5173,4923,4663,4303,3893,3643,3393,3073,2713,2413,2103,179
Accumulated Depreciation-100.0%-87.0088.00108111125---------------
Shares Outstanding-4.1%184191191190189189187186186183184182---------
Float----109---704---3,100---4,100---6,184-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-1.8%-47,888-47,047-42,121-51,523-51,915-57,703-82,887-74,993-88,424-151,538-101,136-82,901-77,085-98,634-52,675-83,903-78,075-125,223-68,641-53,922-80,895
  Share Based Compensation-17.3%6,0007,2548,1497,96610,01912,73812,51811,10320,96122,40524,65723,71423,89821,98723,66723,37125,23625,00824,88024,52225,385
Cashflow From Investing10.8%19,25817,38356,41225,17140,59840,014111,39584,148130,278120,197-83072,95210,45892,74048,668157,038197,767135,48158,25325,290-12,138
Cashflow From Financing349925.0%42,00312.00-18.00-103-4679382,5523,66312,16717,856148,9951,531-241,95711,0774,9066,2497,3064,894
  Buy Backs-3,000--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NKTR Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 21,639$ 21,594
Operating costs and expenses:  
Cost of goods sold8,5347,060
Research and development27,40830,469
General and administrative20,14921,081
Restructuring, impairment and costs of terminated program97521,193
Impairment of goodwill076,501
Total operating costs and expenses57,066156,304
Loss from operations(35,427)(134,710)
Non-operating income (expense):  
Non-cash interest expense on liabilities related to the sales of future royalties(5,531)(6,405)
Interest income4,2204,335
Other income (expense), net(99)(301)
Total non-operating income (expense), net(1,410)(2,371)
Loss before provision for income taxes(36,837)(137,081)
Benefit for income taxes(35)(63)
Net loss$ (36,802)$ (137,018)
Basic net loss per share (in dollars per share)$ (0.19)$ (0.73)
Diluted net loss per share (in dollars per share)$ (0.19)$ (0.73)
Weighted average shares outstanding used in computing basic net loss per share (in shares)194,746188,875
Weighted average shares outstanding used in computing diluted net loss per share (in shares)194,746188,875
Product sales  
Revenue:  
Total revenue$ 6,034$ 4,718
Non-cash royalty revenue related to the sales of future royalties  
Revenue:  
Total revenue15,50816,861
License, collaboration and other revenue  
Revenue:  
Total revenue$ 97$ 15

NKTR Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 48,642$ 35,277
Short-term investments240,596268,339
Accounts receivable3,6171,205
Inventory, net16,23816,101
Other current assets10,7439,779
Total current assets319,836330,701
Property, plant and equipment, net17,47518,856
Long-term investments36,77825,825
Operating lease right-of-use assets17,26718,007
Other assets4,6564,644
Total assets396,012398,033
Current liabilities:  
Accounts payable8,7579,848
Accrued expenses24,28122,162
Operating lease liabilities, current portion19,36819,259
Total current liabilities52,40651,269
Operating lease liabilities, less current portion94,71098,517
Liabilities related to the sales of future royalties, net117,857112,625
Other long-term liabilities4,3344,635
Total liabilities269,307267,046
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2024 or December 31, 2023, respectively00
Common stock, $0.0001 par value; 300,000 shares authorized; 191,909 shares and 191,384 shares issued at March 31, 2024 and December 31, 2023, respectively; 183,624 shares and 191,384 shares outstanding at March 31, 2024 and December 31, 2023, respectively;1919
Capital in excess of par value3,644,1403,608,137
Treasury stock, at cost; 8,285 shares as of March 31, 2024 and none as of December 31, 2023, respectively(3,000)0
Accumulated other comprehensive income (loss)(403)80
Accumulated deficit(3,514,051)(3,477,249)
Total stockholders’ equity126,705130,987
Total liabilities and stockholders’ equity$ 396,012$ 398,033
NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
 CEO
 WEBSITEnektar.com
 INDUSTRYBiotechnology
 EMPLOYEES216

Nektar Therapeutics Frequently Asked Questions


What is the ticker symbol for Nektar Therapeutics? What does NKTR stand for in stocks?

NKTR is the stock ticker symbol of Nektar Therapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nektar Therapeutics (NKTR)?

As of Fri Jun 14 2024, market cap of Nektar Therapeutics is 214.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers. The fair value of Nektar Therapeutics is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nektar Therapeutics is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NKTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nektar Therapeutics a good stock to buy?

The fair value guage provides a quick view whether NKTR is over valued or under valued. Whether Nektar Therapeutics is cheap or expensive depends on the assumptions which impact Nektar Therapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTR.

What is Nektar Therapeutics's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, NKTR's PE ratio (Price to Earnings) is -1.22 and Price to Sales (PS) ratio is 2.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nektar Therapeutics's stock?

In the past 10 years, Nektar Therapeutics has provided -0.219 (multiply by 100 for percentage) rate of return.